245 related articles for article (PubMed ID: 19149536)
1. HIV: a raft-targeting approach for prevention and therapy using plant-derived compounds (review).
Verma SP
Curr Drug Targets; 2009 Jan; 10(1):51-9. PubMed ID: 19149536
[TBL] [Abstract][Full Text] [Related]
2. The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention.
Luo C; Wang K; Liu DQ; Li Y; Zhao QS
Cell Mol Immunol; 2008 Feb; 5(1):1-7. PubMed ID: 18318989
[TBL] [Abstract][Full Text] [Related]
3. Sterol carrier protein-2 selectively alters lipid composition and cholesterol dynamics of caveolae/lipid raft vs nonraft domains in L-cell fibroblast plasma membranes.
Atshaves BP; Gallegos AM; McIntosh AL; Kier AB; Schroeder F
Biochemistry; 2003 Dec; 42(49):14583-98. PubMed ID: 14661971
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy.
Raulin J
Prog Lipid Res; 2002 Jan; 41(1):27-65. PubMed ID: 11694268
[TBL] [Abstract][Full Text] [Related]
5. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions.
Campbell SM; Crowe SM; Mak J
J Clin Virol; 2001 Oct; 22(3):217-27. PubMed ID: 11564586
[TBL] [Abstract][Full Text] [Related]
6. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases.
Fantini J; Garmy N; Mahfoud R; Yahi N
Expert Rev Mol Med; 2002 Dec; 4(27):1-22. PubMed ID: 14987385
[TBL] [Abstract][Full Text] [Related]
7. Lipid rafts in health and disease.
Michel V; Bakovic M
Biol Cell; 2007 Mar; 99(3):129-40. PubMed ID: 17064251
[TBL] [Abstract][Full Text] [Related]
8. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1.
Liao Z; Cimakasky LM; Hampton R; Nguyen DH; Hildreth JE
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1009-19. PubMed ID: 11485618
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytokine signaling in human retinal endothelial cells through modification of caveolae/lipid rafts by docosahexaenoic acid.
Chen W; Jump DB; Esselman WJ; Busik JV
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):18-26. PubMed ID: 17197511
[TBL] [Abstract][Full Text] [Related]
10. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains.
Anderson RG; Jacobson K
Science; 2002 Jun; 296(5574):1821-5. PubMed ID: 12052946
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells.
Popik W; Alce TM; Au WC
J Virol; 2002 May; 76(10):4709-22. PubMed ID: 11967288
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Chung CL; Wang SW; Sun WC; Shu CW; Kao YC; Shiao MS; Chen CL
Biochem Pharmacol; 2018 Aug; 154():39-53. PubMed ID: 29678520
[TBL] [Abstract][Full Text] [Related]
13. The raft-promoting property of virion-associated cholesterol, but not the presence of virion-associated Brij 98 rafts, is a determinant of human immunodeficiency virus type 1 infectivity.
Campbell S; Gaus K; Bittman R; Jessup W; Crowe S; Mak J
J Virol; 2004 Oct; 78(19):10556-65. PubMed ID: 15367622
[TBL] [Abstract][Full Text] [Related]
14. Photoprotection against UVAR: effective triterpenoids require a lipid raft stabilizing chemical structure.
Bayer M; Proksch P; Felsner I; Brenden H; Kohne Z; Walli R; Duong TN; Götz C; Krutmann J; Grether-Beck S
Exp Dermatol; 2011 Nov; 20(11):955-8. PubMed ID: 21824200
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer.
Codini M; Garcia-Gil M; Albi E
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450869
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes.
Sánchez-Wandelmer J; Dávalos A; Herrera E; Giera M; Cano S; de la Peña G; Lasunción MA; Busto R
Biochim Biophys Acta; 2009 Sep; 1788(9):1731-9. PubMed ID: 19433058
[TBL] [Abstract][Full Text] [Related]
17. Nef increases infectivity of HIV via lipid rafts.
Zheng YH; Plemenitas A; Linnemann T; Fackler OT; Peterlin BM
Curr Biol; 2001 Jun; 11(11):875-9. PubMed ID: 11516650
[TBL] [Abstract][Full Text] [Related]
18. Effect of sterol carrier protein-2 expression on sphingolipid distribution in plasma membrane lipid rafts/caveolae.
Atshaves BP; Jefferson JR; McIntosh AL; Gallegos A; McCann BM; Landrock KK; Kier AB; Schroeder F
Lipids; 2007 Oct; 42(10):871-84. PubMed ID: 17680294
[TBL] [Abstract][Full Text] [Related]
19. Lipid rafts, caveolae, caveolin-1, and entry by Chlamydiae into host cells.
Stuart ES; Webley WC; Norkin LC
Exp Cell Res; 2003 Jul; 287(1):67-78. PubMed ID: 12799183
[TBL] [Abstract][Full Text] [Related]
20. Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus.
Kozak SL; Heard JM; Kabat D
J Virol; 2002 Feb; 76(4):1802-15. PubMed ID: 11799176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
